Acura Pharma Announces Fourth Quarter 2016 And Full Year 2016 Financial Results
PALATINE, Ill., March 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2016.
The Company reported net income of $1.5 million, or $0.13 per diluted share, for the fourth quarter of 2016, compared to net loss of $0.9 million or $0.08 per diluted share for the same period in 2015. For 2016 the Company reported a net loss of $7.4 million or $0.62 per diluted share compared to a net loss of $5.0 million or $0.46 per diluted share for 2015.
The Company reported net income of $1.5 million, or $0.13 per diluted share, for the fourth quarter of 2016, compared to net loss of $0.9 million or $0.08 per diluted share for the same period in 2015. For 2016 the Company reported a net loss of $7.4 million or $0.62 per diluted share compared to a net loss of $5.0 million or $0.46 per diluted share for 2015.